These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15795923)

  • 1. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
    Ocio EM; Sanchez-Guijo FM; Diez-Campelo M; Castilla C; Blanco OJ; Caballero D; San Miguel JF
    Am J Hematol; 2005 Apr; 78(4):302-5. PubMed ID: 15795923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
    Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
    WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.
    Ide M; Kawachi Y; Izumi Y; Kasagi K; Ogino T
    Eur J Haematol; 2006 Feb; 76(2):119-23. PubMed ID: 16405432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.
    Kantarci FE; Eren R; Gündoğan C; Huq GE; Doğu MH; Suyanı E
    J Infect Chemother; 2016 Jul; 22(7):483-5. PubMed ID: 26948831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
    Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
    Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab).
    Ibrahim K; Maghfoor I; Elghazaly A; Bakshi N; Mohamed SY; Aljurf M
    Hematol Oncol Stem Cell Ther; 2011; 4(2):100-2. PubMed ID: 21727772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV-8+ lymphoproliferative disorders expands.
    Seliem RM; Griffith RC; Harris NL; Beheshti J; Schiffman FJ; Longtine J; Kutok J; Ferry JA
    Am J Surg Pathol; 2007 Sep; 31(9):1439-45. PubMed ID: 17721201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed variant multicentric Castleman disease treated with rituximab: case report.
    Mian H; Leber B
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):622. PubMed ID: 20921905
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.
    Neuville S; Agbalika F; Rabian C; Brière J; Molina JM
    Am J Hematol; 2005 Aug; 79(4):337-9. PubMed ID: 16044438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease.
    Casquero A; Barroso A; Fernández Guerrero ML; Górgolas M
    Ann Hematol; 2006 Mar; 85(3):185-7. PubMed ID: 16341862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentric Castleman's disease & HIV infection.
    Cotter A; Lambert J; O'Gorman P
    Ir Med J; 2009 Oct; 102(9):294-5. PubMed ID: 19902650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.
    Galeotti C; Tran TA; Franchi-Abella S; Fabre M; Pariente D; Koné-Paut I
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):920-4. PubMed ID: 19131781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
    Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
    Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siltuximab for multicentric Castleman disease.
    Liu YC; Stone K; van Rhee F
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Is the best treatment for HIV-associated multicentric Castleman disease?
    Bower M; Dalla Pria A
    Clin Adv Hematol Oncol; 2012 Mar; 10(3):207-9. PubMed ID: 22402432
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy.
    Koenig G; Stevens TM; Peker D
    Histopathology; 2015 Dec; 67(6):930-2. PubMed ID: 25900626
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of multicentric Castleman's disease in HIV infection with the rare complication of acquired angioedema.
    Fernando I; Scott G
    Int J STD AIDS; 2014 Jun; 25(7):523-5. PubMed ID: 24352125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human herpesvirus 8-related Castleman disease in the absence of HIV infection.
    Dossier A; Meignin V; Fieschi C; Boutboul D; Oksenhendler E; Galicier L
    Clin Infect Dis; 2013 Mar; 56(6):833-42. PubMed ID: 23223599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.
    Műzes G; Sipos F; Csomor J; Sréter L
    APMIS; 2013 Jul; 121(7):668-74. PubMed ID: 23163599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease.
    Estephan FF; Elghetany MT; Berry M; Jones DV
    Cancer Invest; 2005; 23(2):191. PubMed ID: 15813512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.